Advertisement

Meta-Analysis Comparing Drug-Coated Balloons and Percutaneous Transluminal Angioplasty for Infrapopliteal Artery Disease

Published:September 15, 2022DOI:https://doi.org/10.1016/j.amjcard.2022.08.007
      Limited data is available regarding the safety and effectiveness of drug-coated balloon (DCB) versus conventional percutaneous transluminal balloon angioplasty (PTA) in the treatment of critical limb ischemia because of infrapopliteal peripheral arterial disease. We conducted an updated meta-analysis to assess the safety and efficacy of DCB in the treatment of infrapopliteal disease. A database search of PubMed/MEDLINE, EMBASE, and the Cochrane Library was performed by 2 reviewers from inception through November 15, 2021. Randomized trials that compared DCB with conventional PTA in treating infrapopliteal arterial disease were included. The risk ratios (RRs) and 95% confidence intervals (CIs) were reported. A total of 9 trials were included (1,501 participants) in the study. The mean age was 71.1 ± 10.2 years. Regarding the primary end points, treating infrapopliteal arterial disease with DCB had a lower incidence of re-stenosis (RR 0.48, 95% CI 0.33 to 0.70, p = 0.0001) with no significant difference in all-cause mortality (RR 1.11, 95% CI 0.73 to 1.69, p = 0.61), compared with conventional PTA. With regards to the secondary end points, DCB usage was associated with a significant reduction in clinically driven target lesion revascularization (RR 0.54, 95% CI 0.35 to 0.84, p = 0.006) with no significant difference with regards to major target limb amputation and major adverse cardiovascular events (p ≥0.05). In conclusion, among patients with critical limb ischemia secondary to infrapopliteal artery disease, DCB usage was associated with a significantly lower number of restenosis and clinically driven target lesion revascularization compared with conventional PTA. There was no increase in all-cause mortality or major target limb amputation with the use of DCB.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Liistro F
        • Angioli P
        • Ventoruzzo G
        • Ducci K
        • Reccia MR
        • Ricci L
        • Falsini G
        • Scatena A
        • Pieroni M
        • Bolognese L.
        Randomized controlled trial of acotec drug-eluting balloon versus plain balloon for below-the-knee angioplasty.
        JACC Cardiovasc Interv. 2020; 13: 2277-2286
        • Agnelli G
        • Belch JJF
        • Baumgartner I
        • Giovas P
        • Hoffmann U.
        Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review.
        Atherosclerosis. 2020; 293: 94-100
        • Fowkes FGR
        • Rudan D
        • Rudan I
        • Aboyans V
        • Denenberg JO
        • McDermott MM
        • Norman PE
        • Sampson UKA
        • Williams LJ
        • Mensah GA
        • Criqui MH.
        Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis.
        Lancet. 2013; 382: 1329-1340
        • Gerhard-Herman MD
        • Gornik HL
        • Barrett C
        • Barshes NR
        • Corriere MA
        • Drachman DE
        • Fleisher LA
        • Fowkes FGR
        • Hamburg NM
        • Kinlay S
        • Lookstein R
        • Misra S
        • Mureebe L
        • Olin JW
        • Patel RAG
        • Regensteiner JG
        • Schanzer A
        • Shishehbor MH
        • Stewart KJ
        • Treat-Jacobson D
        • Walsh ME.
        2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.
        Circulation. 2017; 135: e726-e779
        • Patel A
        • Irani FG
        • Pua U
        • Tay KH
        • Chong TT
        • Leong S
        • Chan ES-Y
        • Tan GWL
        • Burgmans MC
        • Zhuang KD Da
        • Quek LHH
        • Kwan J
        • Damodharan K
        • Gogna A
        • Tan BP
        • Too CW
        • Chan SXJM
        • Chng SP
        • Yuan W
        • Tan BS
        Randomized controlled trial comparing drug-coated balloon angioplasty versus conventional balloon angioplasty for treating below-the-knee arteries in critical limb ischemia: the SINGA-PACLI Trial.
        Radiology. 2021; 300: 715-724
        • Holmes D.
        Critical limb ischaemia: artery repair.
        Nature. 2017; 548: S41
        • Kudo T
        • Chandra FA
        • Ahn SS.
        The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia: a 10-year experience.
        J Vasc Surg. 2005; 41: 423-435
        • Tepe G
        • Laird J
        • Schneider P
        • Brodmann M
        • Krishnan P
        • Micari A
        • Metzger C
        • Scheinert D
        • Zeller T
        • Cohen DJ
        • Snead DB
        • Alexander B
        • Landini M
        • Jaff MR
        • IN.PACT SFA Trial Investigators
        Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial.
        Circulation. 2015; 131: 495-502
        • Rosenfield K
        • Jaff MR
        • White CJ
        • Rocha-Singh K
        • Mena-Hurtado C
        • Metzger DC
        • Brodmann M
        • Pilger E
        • Zeller T
        • Krishnan P
        • Gammon R
        • Müller-Hülsbeck S
        • Nehler MR
        • Benenati JF
        • Scheinert D
        LEVANT 2 Investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease.
        N Engl J Med. 2015; 373: 145-153
        • Mustapha JA
        • Brodmann M
        • Geraghty PJ
        • Saab F
        • Settlage RA
        • Jaff MR
        • Lutonix BTK Study Investigators
        Drug-coated vs uncoated percutaneous transluminal angioplasty in infrapopliteal arteries: six-month results of the lutonix BTK trial.
        J Invasive Cardiol. 2019; 31: 205-211
        • Zeller T
        • Beschorner U
        • Pilger E
        • Bosiers M
        • Deloose K
        • Peeters P
        • Scheinert D
        • Schulte KL
        • Rastan A
        • Brodmann M.
        Paclitaxel-coated balloon in infrapopliteal arteries: 12-month results from the BIOLUX P-II randomized trial (BIOTRONIK'S-first in man study of the Passeo-18 LUX drug releasing PTA balloon catheter vs the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries.
        JACC Cardiovasc Interv. 2015; 8: 1614-1622
        • Liberati A
        • Altman DG
        • Tetzlaff J
        • Mulrow C
        • Gøtzsche PC
        • Ioannidis JPA
        • Clarke M
        • Devereaux PJ
        • Kleijnen J
        • Moher D.
        The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
        J Clin Epidemiol. 2009; 62: e1-e34
        • Haddad SE
        • Shishani JM
        • Qtaish I
        • Rawashdeh MA
        • Qtaishat BS.
        One year primary patency of infrapopliteal angioplasty using drug- eluting balloons: single center experience at king Hussein medical center.
        J Clin Imaging Sci. 2017; 7: 31
        • Liistro F
        • Porto I
        • Angioli P
        • Grotti S
        • Ricci L
        • Ducci K
        • Falsini G
        • Ventoruzzo G
        • Turini F
        • Bellandi G
        • Bolognese L.
        Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia.
        Circulation. 2013; 128: 615-621
        • Zeller T
        • Micari A
        • Scheinert D
        • Baumgartner I
        • Bosiers M
        • Vermassen FEG
        • Banyai M
        • Shishehbor MH
        • Wang H
        • Brodmann M
        • IN.PACT DEEP Trial Investigators
        The IN.PACT DEEP clinical drug-coated balloon trial: 5-year outcomes.
        JACC Cardiovasc Interv. 2020; 13: 431-443
        • Liistro F
        • Weinberg I
        • Almonacid Popma A
        • Shishehbor MH
        • Deckers S
        • Micari A
        Paclitaxel-coated balloons versus percutaneous transluminal angioplasty for infrapopliteal chronic total occlusions: the. IN:PACT BTK Randomised Trial.
        EuroIntervention. 2022; 17: e1445-e1454
        • Jia X
        • Zhuang B
        • Wang F
        • Gu Y
        • Zhang J
        • Lu X
        • Dai X
        • Liu Z
        • Bi W
        • Liu C
        • Wang S
        • Liistro F
        • Guo W.
        Drug-coated balloon angioplasty compared with uncoated balloons in the treatment of infrapopliteal artery lesions (AcoArt II-BTK).
        J Endovasc Ther. 2021; 28: 215-221
        • Katsanos K
        • Spiliopoulos S
        • Kitrou P
        • Krokidis M
        • Karnabatidis D.
        Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials.
        J Am Heart Assoc. 2018; 7e011245
        • Krishnan P
        • Faries P
        • Niazi K
        • Jain A
        • Sachar R
        • Bachinsky WB
        • Cardenas J
        • Werner M
        • Brodmann M
        • Mustapha JA
        • Mena-Hurtado C
        • Jaff MR
        • Holden AH
        • Lyden SP.
        Stellarex drug-coated balloon for treatment of femoropopliteal disease: twelve-month outcomes from the randomized ILLUMENATE pivotal and pharmacokinetic studies.
        Circulation. 2017; 136: 1102-1113
        • Tepe G
        • Schnorr B
        • Albrecht T
        • Brechtel K
        • Claussen CD
        • Scheller B
        • Speck U
        • Zeller T.
        Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial.
        JACC Cardiovasc Interv. 2015; 8: 102-108
        • Feldman DN
        • Armstrong EJ
        • Aronow HD
        • Gigliotti OS
        • Jaff MR
        • Klein AJ
        • Parikh SA
        • Prasad A
        • Rosenfield K
        • Shishehbor MH
        • Swaminathan RV
        • White CJ.
        SCAI consensus guidelines for device selection in femoral-popliteal arterial interventions.
        Catheter Cardiovasc Interv. 2018; 92: 124-140
        • Waksman R
        • Pakala R.
        Drug-eluting balloon: the comeback kid?.
        Circ Cardiovasc Interv. 2009; 2: 352-358
        • Ng VG
        • Mena C
        • Pietras C
        • Lansky AJ.
        Local delivery of paclitaxel in the treatment of peripheral arterial disease.
        Eur J Clin Invest. 2015; 45: 333-345
        • Katsanos K
        • Spiliopoulos S
        • Karunanithy N
        • Krokidis M
        • Sabharwal T
        • Taylor P.
        Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery.
        J Vasc Surg. 2014; 59 (e8): 1123-1133
        • Katsanos K
        • Spiliopoulos S
        • Kitrou P
        • Krokidis M
        • Paraskevopoulos I
        • Karnabatidis D.
        Risk of death and amputation with use of paclitaxel-coated balloons in the infrapopliteal arteries for treatment of critical limb ischemia: a systematic review and meta-analysis of randomized controlled trials.
        J Vasc Interv Radiol. 2020; 31: 202-212
        • Schneider PA
        • Laird JR
        • Tepe G
        • Brodmann M
        • Zeller T
        • Scheinert D
        • Metzger C
        • Micari A
        • Sachar R
        • Jaff MR
        • Wang H
        • Hasenbank MS
        • Krishnan P
        • IN.PACT SFA Trial Investigators
        Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial.
        Circ Cardiovasc Interv. 2018; 11e005891
      1. United States Food and Drug Administration. Update: treatment of peripheral arterial disease with paclitaxel-coated balloons and paclitaxel-eluting stents potentially associated with increased mortality. Available at: https://www.fda.gov/medical-devices/letters-health-care-providers/august-7-2019-update-treatment-peripheral-arterial-disease-paclitaxel-coated-balloons-and-paclitaxel. Accessed on January 30, 2022.